Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 228,851
  • Shares Outstanding, K 78,914
  • Annual Sales, $ 2,150 K
  • Annual Income, $ -47,150 K
  • 60-Month Beta 2.16
  • Price/Sales 102.36
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.23
  • Number of Estimates 4
  • High Estimate -0.21
  • Low Estimate -0.25
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.76 +5.26%
on 05/17/19
4.00 -27.50%
on 04/30/19
-0.46 (-13.69%)
since 04/17/19
3-Month
2.76 +5.26%
on 05/17/19
4.09 -29.10%
on 03/05/19
unch (unch)
since 02/15/19
52-Week
1.99 +45.73%
on 12/26/18
5.05 -42.57%
on 11/02/18
-0.10 (-3.33%)
since 05/17/18

Most Recent Stories

More News
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?...

ACRX : 2.90 (+3.94%)
AcelRx Pharmaceuticals Reports First Quarter 2019 Financial Results

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings,...

ACRX : 2.90 (+3.94%)
AcelRx Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 8, 2019 / AcelRx Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM Eastern...

ACRX : 2.90 (+3.94%)
What's in the Cards for AcelRx (ACRX) This Earnings Season?

We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

GNMSF : 170.3000 (-0.71%)
HZNP : 25.83 (-4.19%)
ACRX : 2.90 (+3.94%)
INO : 3.34 (-2.34%)
Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRX : 2.90 (+3.94%)
AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019. AcelRx...

ACRX : 2.90 (+3.94%)
Detailed Research: Economic Perspectives on Dave & Buster's Entertainment, AcelRx Pharmaceuticals, Beazer Homes, Houston American Energy, Servotronics, and Apollo Endosurgery -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dave & Buster's Entertainment,...

SVT : 11.41 (-2.73%)
PLAY : 53.83 (+0.41%)
BZH : 9.71 (-4.15%)
ACRX : 2.90 (+3.94%)
APEN : 3.74 (+0.27%)
HUSA : 0.23 (-3.12%)
AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today...

ACRX : 2.90 (+3.94%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 23.80 (-2.34%)
ACRX : 2.90 (+3.94%)
ALPN : 5.95 (+7.40%)
OTIC : 2.81 (-0.71%)
MTEM : 7.47 (-3.36%)
TCDA : 36.06 (-0.19%)
ATNM : 0.31 (+15.97%)
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRX : 2.90 (+3.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ACRX with:

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 3.04
1st Resistance Point 2.97
Last Price 2.90
1st Support Level 2.79
2nd Support Level 2.69

See More

52-Week High 5.05
Fibonacci 61.8% 3.88
Fibonacci 50% 3.52
Fibonacci 38.2% 3.16
Last Price 2.90
52-Week Low 1.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar